Growth Metrics

Halozyme Therapeutics (HALO) Long-Term Deferred Tax (2021 - 2025)

Halozyme Therapeutics (HALO) has disclosed Long-Term Deferred Tax for 5 consecutive years, with $5.2 million as the latest value for Q1 2025.

  • On a quarterly basis, Long-Term Deferred Tax changed N/A to $5.2 million in Q1 2025 year-over-year; TTM through Mar 2025 was $5.2 million, a N/A change, with the full-year FY2024 number at $3.9 million, down 12.11% from a year prior.
  • Long-Term Deferred Tax was $5.2 million for Q1 2025 at Halozyme Therapeutics, up from $3.9 million in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $155.4 million in Q4 2021 to a low of $3.9 million in Q4 2024.
  • A 5-year average of $57.1 million and a median of $29.8 million in 2023 define the central range for Long-Term Deferred Tax.
  • Peak YoY movement for Long-Term Deferred Tax: crashed 90.13% in 2023, then dropped 12.11% in 2024.
  • Halozyme Therapeutics' Long-Term Deferred Tax stood at $155.4 million in 2021, then tumbled by 71.42% to $44.4 million in 2022, then plummeted by 90.13% to $4.4 million in 2023, then decreased by 12.11% to $3.9 million in 2024, then skyrocketed by 34.63% to $5.2 million in 2025.
  • Per Business Quant, the three most recent readings for HALO's Long-Term Deferred Tax are $5.2 million (Q1 2025), $3.9 million (Q4 2024), and $4.4 million (Q4 2023).